1. Home
  2. PRLD vs MODD Comparison

PRLD vs MODD Comparison

Compare PRLD & MODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • MODD
  • Stock Information
  • Founded
  • PRLD 2016
  • MODD 1998
  • Country
  • PRLD United States
  • MODD United States
  • Employees
  • PRLD N/A
  • MODD N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • MODD Industrial Specialties
  • Sector
  • PRLD Health Care
  • MODD Health Care
  • Exchange
  • PRLD Nasdaq
  • MODD Nasdaq
  • Market Cap
  • PRLD 44.0M
  • MODD 46.3M
  • IPO Year
  • PRLD 2020
  • MODD N/A
  • Fundamental
  • Price
  • PRLD $1.19
  • MODD $0.71
  • Analyst Decision
  • PRLD Strong Buy
  • MODD
  • Analyst Count
  • PRLD 3
  • MODD 0
  • Target Price
  • PRLD $4.00
  • MODD N/A
  • AVG Volume (30 Days)
  • PRLD 223.1K
  • MODD 55.0K
  • Earning Date
  • PRLD 11-05-2025
  • MODD 08-14-2025
  • Dividend Yield
  • PRLD N/A
  • MODD N/A
  • EPS Growth
  • PRLD N/A
  • MODD N/A
  • EPS
  • PRLD N/A
  • MODD N/A
  • Revenue
  • PRLD $7,000,000.00
  • MODD N/A
  • Revenue This Year
  • PRLD N/A
  • MODD N/A
  • Revenue Next Year
  • PRLD N/A
  • MODD N/A
  • P/E Ratio
  • PRLD N/A
  • MODD N/A
  • Revenue Growth
  • PRLD N/A
  • MODD N/A
  • 52 Week Low
  • PRLD $0.61
  • MODD $0.63
  • 52 Week High
  • PRLD $5.53
  • MODD $2.50
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 56.86
  • MODD 46.14
  • Support Level
  • PRLD $1.10
  • MODD $0.69
  • Resistance Level
  • PRLD $1.26
  • MODD $0.75
  • Average True Range (ATR)
  • PRLD 0.15
  • MODD 0.04
  • MACD
  • PRLD -0.00
  • MODD -0.00
  • Stochastic Oscillator
  • PRLD 70.65
  • MODD 22.76

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

Share on Social Networks: